Safety of Effivia®, a Bevacizumab Biosimilar

Post-marketing Safety of Effivia®, a Bevacizumab Biosimilar: Phase IV, Observational, Multicenter Clinical Study in Mexican Population

This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.

Inclusion Criteria:

• Male and female patients, 18 years and older.
• Patients with metastatic colorectal cancer,unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, or epithelial ovarian, fallopian tube, or primary peritoneal cancer naive to bevacizumab therapy (Effivia®).
• Provide written informed consent.

Exclusion Criteria:

• History of recent surgery or wound healing complications.
• History of gastrointestinal perforations or fistula.
• History of renal injury and proteinuria.
• Recent surgical intervention.
• Pregnant or nursing women.
• History of bevacizumab, monoclonal antibodies, or CHO cells-derived products hypersensitivity.
• Other safety concerns or bevacizumab contraindications.